BRISBANE, Calif. / Mar 06, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference.
CareDx’s management is scheduled to present at the Raymond James & Associates’ 44th Annual Institutional Investors Conference on Monday, March 6th, 2023, at 4:35 PM ET. To listen to the webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Last Trade: | US$12.97 |
Daily Change: | 0.46 3.68 |
Daily Volume: | 1,221,504 |
Market Cap: | US$690.390M |
August 06, 2025 August 06, 2025 July 18, 2025 April 30, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load